-
Akums Drugs Reports 12% EBITDA and 15% PAT Growth in Q3 FY25
New Delhi, February 7, 2025: Akums Drugs and Pharmaceuticals Ltd., has announced its consolidated financial results for the quarter ended December 31, 2024, delivering 12% increase in Adjusted EBITDA on year on year basis. Key Highlights: Quarter ended December 31, 2024 9 months ended December 31, 2024 •    Adj EBITDA Margin at
Search
About
At NexGen Consulting, we specialize in strategic media planning that helps brands secure the best possible coverage—across both digital and print media. With a focus on visibility, credibility, and audience engagement, we ensure your message reaches the right people, at the right time, through the right platforms.
As a results-driven media consulting agency, we work closely with businesses, startups, and professionals to build strong media presence and brand authority. Whether you need features in top publications, digital news coverage, influencer reach, or targeted content placement, our team ensures maximum impact with smart, data-backed planning.
Archive
Categories
Recent Posts
- 43rd Sri Vishwakarma Brahma Rathotsava and Janajaagruthi Convention
- The Grok AI Controversy: How Unchecked Innovation Triggered Global Alarm
- Aditya Rawal on Taking a Challenging Role in Prime Video’s Daldal
- Coforge Named Leader in ISG Provider Lens 2025 for Multi-Cloud Services
- Budget 2026 Should Unlock Growth and Investment in India’s Hospitality and Tourism Sector
Gallery






